PTJ
COLL icon

Paul Tudor Jones’s Collegium Pharmaceutical COLL Stock Holding History

Paul Tudor Jones’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,956
Closed -$462K – 3655
2026
Q1 		$462K Sell
13,956
-3,220
-19% -$136K ﹤0.01% 2873
2025
Q4 		$795K Buy
17,176
+1,166
+7% +$48.8K ﹤0.01% 2434
2025
Q3 		$560K Buy
+16,010
New +$557K ﹤0.01% 2634
2017
Q2 		– Sell
-15,000
Closed -$151K – 1076
2017
Q1 		$151K Buy
+15,000
New +$223K ﹤0.01% 1268

Other funds holding COLL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Paul Tudor Jones's COLL Position: Q2 2026 in Review

Paul Tudor Jones sold out of Collegium Pharmaceutical (COLL) in Q2 2026, closing a stake of 13,956 shares — an estimated $462K sold.

Paul Tudor Jones first reported a position in COLL in Q1 2017 and held it in 4 quarters. The position peaked at $795K in Q4 2025. 277 funds tracked by Wall St. Rank hold COLL as of Q2 2026.

  • Paul Tudor Jones reported no remaining Collegium Pharmaceutical position as of Q2 2026 after selling out during the quarter.
  • Paul Tudor Jones sold 13,956 Collegium Pharmaceutical shares in Q2 2026, an estimated $462K.
  • Paul Tudor Jones first reported a position in Collegium Pharmaceutical in Q1 2017 and held it in 4 quarters.
  • Paul Tudor Jones's Collegium Pharmaceutical position peaked at $795K in Q4 2025.
  • 277 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.